DAPK1 and chronic myelogenous leukemia, BCR-ABL1 positive: The present study provides an insight into the understanding of imatinib resistance in CML progression and proposes that the determination of DAPK1 methylation may be a criterion to use an additional agent in the treatment of CML (i.e., decitabine).